Tandem Diabetes Care (NASDAQ:TNDM) Trading Up 7.9%

Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Get Free Report) traded up 7.9% during mid-day trading on Tuesday . The stock traded as high as $34.36 and last traded at $34.24. 229,124 shares were traded during trading, a decline of 87% from the average session volume of 1,715,144 shares. The stock had previously closed at $31.73.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on the stock. Citigroup upped their target price on shares of Tandem Diabetes Care from $31.00 to $38.00 and gave the company a "neutral" rating in a research report on Wednesday, April 3rd. StockNews.com upgraded shares of Tandem Diabetes Care from a "sell" rating to a "hold" rating in a report on Friday. Finally, Stifel Nicolaus upped their target price on shares of Tandem Diabetes Care from $37.00 to $40.00 and gave the stock a "buy" rating in a research note on Tuesday. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and five have issued a buy rating to the company's stock. Based on data from MarketBeat, Tandem Diabetes Care currently has a consensus rating of "Hold" and an average price target of $37.27.

Tandem Diabetes Care Price Performance

The stock's 50-day moving average is $30.09 and its 200 day moving average is $25.00. The company has a debt-to-equity ratio of 0.91, a current ratio of 3.83 and a quick ratio of 3.02. The company has a market cap of $2.26 billion, a PE ratio of -10.17 and a beta of 1.11.

Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) last announced its quarterly earnings data on Wednesday, February 21st. The medical device company reported ($0.27) earnings per share for the quarter, missing analysts' consensus estimates of ($0.23) by ($0.04). The firm had revenue of $196.80 million during the quarter, compared to analyst estimates of $204.86 million. Tandem Diabetes Care had a negative net margin of 29.77% and a negative return on equity of 31.48%. On average, equities analysts anticipate that Tandem Diabetes Care, Inc. will post -1.62 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the company. RiverPark Advisors LLC acquired a new stake in Tandem Diabetes Care during the fourth quarter worth about $27,000. MCF Advisors LLC grew its holdings in Tandem Diabetes Care by 79.3% during the first quarter. MCF Advisors LLC now owns 1,006 shares of the medical device company's stock worth $36,000 after acquiring an additional 445 shares during the period. Signaturefd LLC grew its holdings in Tandem Diabetes Care by 871.8% during the fourth quarter. Signaturefd LLC now owns 1,691 shares of the medical device company's stock worth $50,000 after acquiring an additional 1,517 shares during the period. Arcadia Investment Management Corp MI grew its holdings in Tandem Diabetes Care by 141.6% during the first quarter. Arcadia Investment Management Corp MI now owns 1,851 shares of the medical device company's stock worth $66,000 after acquiring an additional 1,085 shares during the period. Finally, GAMMA Investing LLC acquired a new stake in Tandem Diabetes Care during the fourth quarter worth about $73,000.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.